Evidence map›Paper›PMID 37349639›Full record

ArticleJournal of general internal medicine2023

Central Nervous System-Active Prescriptions in Older Veterans: Trends in Prevalence, Prescribers, and High-risk Populations.

Robert E Burke, Lindsay Pelcher, Andrew Tjader, Amy M Linsky, Carolyn T Thorpe, Justin P Turner, Liam Rose

Open access · bronzeAbstract read
In one paragraph

Article in Journal of general internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Robert E BurkeCenter for Health Equity Research and Promotion, Corporal Crescenz VA Medical Center, Philadelphia, PA, USA. Robert.Burke2@pennmedicine.upenn.edu.
Lindsay PelcherCenter for Health Equity Research and Promotion, Pittsburgh VA Medical Center, Pittsburgh, PA, USA.
Andrew TjaderCenter for Health Equity Research and Promotion, Pittsburgh VA Medical Center, Pittsburgh, PA, USA.
Amy M LinskyCenter for Healthcare Organization and Implementation Research, VA Boston Healthcare System, Boston, MA, USA.
Carolyn T ThorpeCenter for Health Equity Research and Promotion, Pittsburgh VA Medical Center, Pittsburgh, PA, USA.
Justin P TurnerCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Liam RoseHealth Economics Resource Center, Palo Alto VA Medical Center, Palo Alto, CA, USA.
VA Pittsburgh Healthcare System · USBoston University · USInstitut Universitaire de Gériatrie de Montréal · CARobert Morris University · USUniversity of North Carolina at Chapel Hill · USVA Palo Alto Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known about the prevalence or chronicity of prescriptions of central nervous system-active (CNS-active) medications in older Veterans.

objectiveWe sought to describe (1) the prevalence and trends in prescription of CNS-active medications in older Veterans over time; (2) variation in prescriptions across high-risk groups; and (3) where the prescription originated (VA or Medicare Part D).

designRetrospective cohort study from 2015 to 2019.

participantsVeterans age ≥ 65 enrolled in the Medicare and the VA residing in Veterans Integrated Service Network 4 (incorporating Pennsylvania and parts of surrounding states). MAIN MEASURES: Drug classes included antipsychotics, gabapentinoids, muscle relaxants, opioids, sedative-hypnotics, and anticholinergics. We described prescribing patterns overall and in three subgroups: Veterans with a diagnosis of dementia, Veterans with high predicted utilization, and frail Veterans. We calculated both prevalence (any fill) and percent of days covered (chronicity) for each drug class, and CNS-active polypharmacy (≥ 2 CNS-active medications) rates in each year in these groups. KEY

resultsThe sample included 460,142 Veterans and 1,862,544 person-years. While opioid and sedative-hypnotic prevalence decreased, gabapentinoids exhibited the largest increase in both prevalence and percent of days covered. Each subgroup exhibited different patterns of prescribing, but all had double the rates of CNS-active polypharmacy compared to the overall study population. Opioid and sedative-hypnotic prevalence was higher in Medicare Part D prescriptions, but the percent of days covered of nearly all drug classes was higher in VA prescriptions.

conclusionsThe concurrent increase of gabapentinoid prescribing paralleling a decrease in opioid and sedative-hypnotics is a new phenomenon that merits further evaluation of patient safety outcomes. In addition, we found substantial potential opportunities for deprescribing CNS-active medications in high-risk groups. Finally, the increased chronicity of VA prescriptions versus Medicare Part D is novel and should be further evaluated in terms of its mechanism and impact on Medicare-VA dual users.

Indexed as

Medicare Part DVeteransAgedAnalgesics, OpioidCentral Nervous SystemDrug PrescriptionsHumansHypnotics and SedativesPrevalenceRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsAnalgesics, OpioidHypnotics and Sedatives

Identifiers

PMID37349639
PMCPMC10713889
OpenAlexW4381715897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.